121 related articles for article (PubMed ID: 29719371)
21. Pharmacoeconomic series: Part 3. Applying pharmacoeconomic and quality-of-life measures to the formulary management process.
Skaer TL
Hosp Formul; 1993 Jun; 28(6):577-84. PubMed ID: 10126586
[TBL] [Abstract][Full Text] [Related]
22. Formularies: the role of pharmacy-and-therapeutics (P&T) committees.
Summers KH; Szeinbach SL
Clin Ther; 1993; 15(2):433-41; discussion 432. PubMed ID: 8519049
[TBL] [Abstract][Full Text] [Related]
23. P & T Committee formulary requests: criteria for admission.
Weintraub M; Guttmacher L
Hosp Formul; 1984 Oct; 19(10):975-7, 980. PubMed ID: 10268315
[TBL] [Abstract][Full Text] [Related]
24. Committee on Natural Toxins and Food Allergens. Marine and freshwater toxins.
Hungerford JM
J AOAC Int; 2005; 88(1):299-313. PubMed ID: 15759755
[TBL] [Abstract][Full Text] [Related]
25. An organizational tool to describe and evaluate group performance in the health care setting.
Nair KV; Ascione FJ; Bagozzi RP; Mannebach MA
J Am Pharm Assoc (Wash); 2001; 41(4):608-17. PubMed ID: 11486987
[TBL] [Abstract][Full Text] [Related]
26. Use of pharmacoeconomic data in making hospital formulary decisions.
Odedina FT; Sullivan J; Nash R; Clemmons CD
Am J Health Syst Pharm; 2002 Aug; 59(15):1441-4. PubMed ID: 12166044
[TBL] [Abstract][Full Text] [Related]
27. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
Allen D; Gillen E; Rixson L
JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
[TBL] [Abstract][Full Text] [Related]
28. Six Sigma: not for the faint of heart.
Benedetto AR
Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
[TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomics and clinical practice guidelines. A survey of attitudes in Swedish formulary committees.
Anell A; Svarvar P
Pharmacoeconomics; 2000 Feb; 17(2):175-85. PubMed ID: 10947340
[TBL] [Abstract][Full Text] [Related]
30. Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.
Shalansky SJ; Virk R; Ackman M; Jackevicius C; Kertland H; Tsuyuki R; Humphries K;
Can J Cardiol; 2003 Feb; 19(2):173-9. PubMed ID: 12601443
[TBL] [Abstract][Full Text] [Related]
31. Application of pharmacoeconomics to formulary management in a health system setting.
Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
[TBL] [Abstract][Full Text] [Related]
32. Developing Drug Reports for the Pharmacy and Therapeutics Committee.
Longe RL; Riley MW
Am J Hosp Pharm; 1976 Jul; 33(7):651-2. PubMed ID: 941920
[TBL] [Abstract][Full Text] [Related]
33. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
[TBL] [Abstract][Full Text] [Related]
34. Formularies in integrated health systems: Sharp HealthCare.
Rizos AL; Levy E; Furnier J; Crowley K
Am J Health Syst Pharm; 1996 Feb; 53(3):274-8. PubMed ID: 8808022
[TBL] [Abstract][Full Text] [Related]
35. P & T Committee interview: strategies to ensure an effective formulary system.
Riff L; Hutchinson R
Hosp Formul; 1988 Nov; 23(11):901-4, 907-8. PubMed ID: 10290754
[TBL] [Abstract][Full Text] [Related]
36. Formulary decisions for pre-1938 medications.
Culley CM; Carroll BA; Skledar SJ
Am J Health Syst Pharm; 2008 Jul; 65(14):1363-7. PubMed ID: 18593683
[TBL] [Abstract][Full Text] [Related]
37. How to use structured decision making in developing therapeutic, cost-effective formulary systems.
Crane VS
Hosp Formul; 1993 Oct; 28(10):859-62, 865-7. PubMed ID: 10129135
[TBL] [Abstract][Full Text] [Related]
38. Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development.
Friesen P; Caplan AL; Miller JE
J Clin Pharm Ther; 2020 Apr; 45(2):249-255. PubMed ID: 31657022
[TBL] [Abstract][Full Text] [Related]
39. Rapid Development of a Tool for Prioritizing Patients with Coronavirus Disease 2019 for Intensive Care.
Roy M; Hansen P; Sullivan T; Ombler F; Kiore M; Stapleton A; Carr C
Crit Care Explor; 2021 Mar; 3(3):e0368. PubMed ID: 33786444
[TBL] [Abstract][Full Text] [Related]
40. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs.
Aspinall SL; Good CB; Glassman PA; Valentino MA
Med Care; 2005 Jul; 43(7 Suppl):20-6. PubMed ID: 16056005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
